Cargando…

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma

OBJECTIVE: To evaluate the efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma. METHODS: A total of 53 advanced lung adenocarcinoma patients hospitalized between July 2013 and June 2016 with a performance status ≤2 were enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Zhong, Lv, Wei-Ze, Wang, Si-Yang, Zou, Jin-Lin, Con, Yun-Yan, Wang, Zhi-Hui, Xiao, Mei, Peng, Pei-Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700764/ https://www.ncbi.nlm.nih.gov/pubmed/29200887 http://dx.doi.org/10.2147/CMAR.S150975

Ejemplares similares

Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
por: Wu, Mindan, et al.
Publicado: (2023)

A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma
por: Lu, Yiyu, et al.
Publicado: (2016)

Safety and Efficacy of Pemetrexed in Maintenance Therapy of Non-Small Cell Lung Cancer
por: Velez, Michel, et al.
Publicado: (2012)

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
por: Zhao, Xinmin, et al.
Publicado: (2017)

Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population
por: Pankaj, Goyal, et al.
Publicado: (2016)

Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting
por: Li, Jianjie, et al.
Publicado: (2021)

The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis
por: Zhong, Anyuan, et al.
Publicado: (2015)

Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma
por: YANG, MIN, et al.
Publicado: (2014)

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
por: Jo, Jaemin, et al.
Publicado: (2018)

PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy
por: Qin, Yi, et al.
Publicado: (2020)

Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis
por: Zhang, Guoqiao, et al.
Publicado: (2019)

Pemetrexed induced pneumonitis
por: Dhakal, Binod, et al.
Publicado: (2011)

Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience
por: Lin, Liping, et al.
Publicado: (2016)

Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma
por: Wang, Jia-Ni, et al.
Publicado: (2021)

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy
por: Zhou, Shengyu, et al.
Publicado: (2018)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2015)

Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study
por: Wang, Rui, et al.
Publicado: (2022)

Single pemetrexed is noninferior to platinum-based pemetrexed doublet as first-line treatment on elderly Chinese patients with advanced nonsquamous nonsmall cell lung cancer
por: Pu, Xiaolin, et al.
Publicado: (2017)

Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma
por: Peng, Pei-Jian, et al.
Publicado: (2015)

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
por: Tsutani, Yasuhiro, et al.
Publicado: (2018)

Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
por: Jung, Minkyu, et al.
Publicado: (2013)

Pemetrexed for epithelioid haemangioendothelioma of the pleura
por: Kanemura, Shingo, et al.
Publicado: (2016)

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
por: Guo, Long-Hua, et al.
Publicado: (2020)

Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy
por: MOU, WENJUN, et al.
Publicado: (2014)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Analysis of pemetrexed-based chemotherapy in the treatment of advanced colorectal cancer
por: Yu, Zhengyi, et al.
Publicado: (2020)

Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts
por: Cui, Jiadong, et al.
Publicado: (2018)

Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review
por: Wang, Haiyong, et al.
Publicado: (2016)

Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study
por: Gu, Xiaodong, et al.
Publicado: (2022)

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
por: Jia, Bo, et al.
Publicado: (2020)

PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed
por: Zhang, Pei, et al.
Publicado: (2017)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Phase II Study of a Bi-Weekly Chemotherapy Regimen of Combined Liposomal Paclitaxel and Nedaplatin for the Treatment of Advanced Squamous Cell Lung Cancer
por: Lv, Wei-Ze, et al.
Publicado: (2019)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients
por: Zhou, Xueheng, et al.
Publicado: (2019)

Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study [Retraction]
Publicado: (2022)

Eyelid and feet edema induced by pemetrexed
por: Kastalli, Sarrah, et al.
Publicado: (2016)

Nephrotoxicity in a Patient Treated with Pemetrexed
por: Zajjari, Y., et al.
Publicado: (2017)

Pemetrexed Induced Life-threatening Anaphylaxis
por: Rajasurya, Venkat, et al.
Publicado: (2019)

Edema of the face and extremities secondary to pemetrexed
por: Doyle, Thomas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5lfl161sme5d1kln5pb2cilln0